Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome.
A low dose of oral etidronate (3.7 mg kg(-1) d(-1)) was administered for immobilization hypercalcaemia associated with Guillain-Barré syndrome in a 12-y-old boy. There was a slight increase in osteoblastic bone formation reflected by alkaline phosphatase and in particular bone-specific alkaline phosphatase during the treatment and serum calcium decreased to the normal range within 2 wk. No adverse side effects were observed and the patient's linear growth subsequently progressed.


CONCLUSIONS
A low dose of oral etidronate is safe and effective for treatment of immobilization hypercalcaemia in children, without inhibiting bone formation.
Go
T
T
Department of Paediatrics, Otsu Red Cross Hospital, Japan. masumigo@mbox.kyoto-inet.or.jp
D000284:Administration, Oral; D002648:Child; D012968:Etidronic Acid / Q000008:administration & dosage*; D020275:Guillain-Barre Syndrome / Q000150:complications*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D018476:Hypokinesia / Q000150:complications*; D008297:Male
D012968:Etidronic Acid